eMedicine Specialties > Dermatology > Benign Neoplasms

Dermatofibroma

Author: Joseph C Pierson, MD, Consulting Staff, Department of Dermatology, Keller Army Community Hospital
Coauthor(s): Diane M Pierson, DO, Fellow, Department of Hematopathology, MD Anderson Cancer Center, University of Texas at Houston
Contributor Information and Disclosures

Updated: May 22, 2008

Introduction

Background

Dermatofibroma (DF) is a common cutaneous nodule of unknown etiology that occurs more often in women. The lesion frequently develops on the extremities (mostly the lower legs) and is usually asymptomatic, although pruritus and tenderness are not uncommon. The latter feature is seen in a sufficient number of patients to make DF the most prevalent of all painful skin tumors. A number of well-described, histologic subtypes have been reported. Removal of the tumor is not necessary unless diagnostic uncertainty exists or particularly troubling symptoms are present.

Pathophysiology

The precise mechanism for the development of DF is unknown. Rather than a reactive tissue change, DF seems more likely to be a neoplastic process because of the persistent nature of the lesion and the demonstration that it is a clonal proliferative growth.1 Clonality, of course, by itself, is not necessarily synonymous with a neoplastic process; it has been demonstrated in inflammatory conditions, including atopic dermatitis, lichen sclerosis, and psoriasis.

Immunohistochemical testing with antibodies to factor XIIIa is frequently positive in DF, while antibodies to MAC 387 show less consistent results. The former antibody labels fibroblasts (dermal dendrocytes), while the latter labels monocyte-derived macrophages (histiocytes). Controversy exists as to whether the factor XIIIa positivity occurs within the actual tumor cells of DF or simply labels the reactive stromal cells; hence, the cell of origin for the spindle cell proliferation of DF is debatable. The cell surface proteoglycan, syndecan-1, may play a role in the growth of DF.2 Transforming growth factor-beta signaling might be a trigger of the fibrosis seen in DF.3

Frequency

United States

DF is relatively common.

International

Incidence is probably similar to that in the United States.

Mortality/Morbidity

DF is regarded as a benign lesion; however, discomfort from pain or itching may be significant. The few case reports of metastatic DF are disputable from the standpoint of histologic diagnosis. Such reported lesions were highly cellular, of large size, and locally recurrent.4 Indolent pulmonary metastases also were observed.

Race

Frequency appears to be similar in all races.

Sex

Females are affected more commonly than males, with a male-to-female ratio of 1:4.

Age

DF can occur in patients of any age, but it usually develops in young adulthood. Approximately 20% of the lesions occur before age 17 years.

Clinical

History

DFs typically arise slowly and most often occur as a solitary nodule on an extremity, particularly the lower leg, but any cutaneous site is possible. Several lesions may be present, but only rarely are multiple (ie, 15 or more) tumors found. This multiple variant is seen most frequently in the setting of autoimmune disease or altered immunity, such as systemic lupus erythematosus, HIV infection, or leukemia and may be indicative of worsening immunoreactivity. Mild regression has been reported with clinical improvement of the underlying disorder. Conversely, drugs to treat the underlying disorders have also been implicated in causation. Multiple clustered DFs also have been reported.5 Patients may describe a hard mole or unusual scar and may be concerned about the possibility of skin cancer.

DFs are characteristically asymptomatic, but itching and pain often are noted. They are the most common of all painful skin tumors.6 Women who shave their legs may be bothered by the razor traumatizing the lesion in that region, causing pain, bleeding, erosive changes, and ulceration. Although cases of unusually rapid growth exist, most DFs remain static for decades or persist indefinitely. Uncommon reports describe spontaneous regression,7 and this may yield postinflammatory hypopigmentation.

Physical

Typically, the clinical appearance is a solitary, 0.5- to 1-cm nodule. A sizable minority of patients may have several lesions, but rarely are more than 15 lesions present. The overlying skin can range from flesh to gray, yellow, orange, pink, red, purple, blue, brown, or black, or a combination of hues (see Media File 1). On palpation, the hard nodule may feel like a frozen pea or a small pebble fixed to the skin surface and is freely movable over the subcutis. Tenderness may be elicited with manipulation of the lesion.

The characteristic tethering of the overlying epidermis to the underlying lesion with lateral compression, called the dimple sign, may be a useful clinical sign for diagnosis.8 The dimple sign is not unique to DF, and dermatoscopy may be useful in supporting the clinical impression.9

The extremities are the most common sites of involvement, particularly the lower legs. Although any cutaneous site can be seen, palm and sole involvement is rare. Giant (>5 cm in diameter), atrophic, atypical polypoid and DF with satellitosis variants have been reported.

Causes

Historically attributed to some traumatic insult to the skin (eg, arthropod bite), the cause of DF is unknown. Because of its persistent nature, DF is probably better categorized as a neoplastic process rather than a reactive tissue change. A study of eruptive DFs in a kindred suggests that a genetic component may exist.10

More on Dermatofibroma

Overview: Dermatofibroma
Differential Diagnoses & Workup: Dermatofibroma
Treatment & Medication: Dermatofibroma
Follow-up: Dermatofibroma
Multimedia: Dermatofibroma
References
[ CLOSE WINDOW ]

References

  1. Chen TC, Kuo T, Chan HL. Dermatofibroma is a clonal proliferative disease. J Cutan Pathol. Jan 2000;27(1):36-9. [Medline].

  2. Sellheyer K, Smoller BR. Dermatofibroma: upregulation of syndecan-1 expression in mesenchymal tissue. Am J Dermatopathol. Oct 2003;25(5):392-8. [Medline].

  3. Kubo M, Ihn H, Yamane K, Tamaki K. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans. Br J Dermatol. May 2006;154(5):919-25. [Medline].

  4. Colome-Grimmer MI, Evans HL. Metastasizing cellular dermatofibroma. A report of two cases. Am J Surg Pathol. Nov 1996;20(11):1361-7. [Medline].

  5. De Unamuno P, Carames Y, Fernandez-Lopez E, Hernandez-Martin A, Peña C. Congenital multiple clustered dermatofibroma. Br J Dermatol. May 2000;142(5):1040-3. [Medline].

  6. Naversen DN, Trask DM, Watson FH, Burket JM. Painful tumors of the skin: "LEND AN EGG". J Am Acad Dermatol. Feb 1993;28(2 Pt 2):298-300. [Medline].

  7. Niemi KM. The benign fibrohistiocytic tumours of the skin. Acta Derm Venereol Suppl (Stockh). 1970;50(63):Suppl 63:1-66. [Medline].

  8. Fitzpatrick TB, Gilchrest BA. Dimple sign to differentiate benign from malignant pigmented cutaneous lesions. N Engl J Med. Jun 30 1977;296(26):1518. [Medline].

  9. Meffert JJ, Peake MF, Wilde JL. 'Dimpling' is not unique to dermatofibromas. Dermatology. 1997;195(4):384-6. [Medline].

  10. Samlaska C, Bennion S. Eruptive dermatofibromas in a kindred. Cutis. Mar 2002;69(3):187-8, 190. [Medline].

  11. Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas: a prospective morphological study of 412 cases. Arch Dermatol. Jan 2008;144(1):75-83. [Medline].

  12. Goldblum JR, Tuthill RJ. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol. Apr 1997;19(2):147-53. [Medline].

  13. Kim HJ, Lee JY, Kim SH, Seo YJ, Lee JH, Park JK, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol. Aug 2007;157(2):319-24. [Medline].

  14. Horenstein MG, Prieto VG, Nuckols JD, Burchette JL, Shea CR. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?. Am J Surg Pathol. Jul 2000;24(7):996-1003. [Medline].

  15. Zelger BG, Zelger B. [Dermatofibroma. A clinico-pathologic classification scheme]. Pathologe. Nov 1998;19(6):412-9. [Medline].

  16. González-Vela MC, Val-Bernal JF, Martino M, González-López MA, García-Alberdi E, Hermana S. Sclerotic fibroma-like dermatofibroma: an uncommon distinctive variant of dermatofibroma. Histol Histopathol. Jul 2005;20(3):801-6. [Medline].

  17. King R, Googe PB, Page RN, Mihm MC Jr. Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. Mod Pathol. Aug 2005;18(8):1043-7. [Medline].

  18. Kovach BT, Boyd AS. Melanoma associated with a dermatofibroma. J Cutan Pathol. May 2007;34(5):420-2. [Medline].

  19. Weber PJ, Moody BR, Foster JA. Inverted pyramidal biopsy. Dermatol Surg. Jul 2001;27(7):681-4. [Medline].

  20. Krupa Shankar DS, Kushalappa AA, Suma KS, Pai SA. Multiple dermatofibromas on face treated with carbon dioxide laser. Indian J Dermatol Venereol Leprol. May-Jun 2007;73(3):194-5. [Medline].

  21. Aiba S, Terui T, Tagami H. Dermatofibroma with diffuse eosinophilic infiltrate. Am J Dermatopathol. Jun 2000;22(3):281-4. [Medline].

  22. Alexandrescu DT, Wiernik PH. Multiple eruptive dermatofibromas occurring in a patient with chronic myelogenous leukemia. Arch Dermatol. Mar 2005;141(3):397-8. [Medline].

  23. Aydin E, Vardareli OS, Bilezikçi B, Ozgirgin ON. [Dermatofibroma accompanied by perforating dermatosis in the auricle: a case report]. Kulak Burun Bogaz Ihtis Derg. 2005;15(3-4):83-6. [Medline].

  24. Curcó N, Jucglà A, Bordas X, Moreno A. Dermatofibroma with spreading satellitosis. J Am Acad Dermatol. Dec 1992;27(6 Pt 1):1017-9. [Medline].

  25. Evans J, Clarke T, Mattacks CA, Pond CM. Dermatofibromas and arthropod bites: is there any evidence to link the two?. Lancet. Jul 1 1989;2(8653):36-7. [Medline].

  26. Fuciarelli K, Cohen PR. Sebaceous hyperplasia: a clue to the diagnosis of dermatofibroma. J Am Acad Dermatol. Jan 2001;44(1):94-5. [Medline].

  27. Heenan PJ. Tumors of the fibrous tissue involving the skin. In: Elder D, ed. Lever's Histopathology of the Skin. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1997:847-53.

  28. Hong SB, Yang MH, Lee MH, Haw CR. Dermatofibroma-like atypical granular cell tumour. Acta Derm Venereol. 2005;85(2):179-80. [Medline].

  29. Lookingbill DP. A malignant dimple. N Engl J Med. Oct 13 1977;297(15):841-2. [Medline].

  30. Requena L, Fariña MC, Fuente C, Piqué E, Olivares M, Martín L, et al. Giant dermatofibroma. A little-known clinical variant of dermatofibroma. J Am Acad Dermatol. May 1994;30(5 Pt 1):714-8. [Medline].

  31. Sanchez RL. The elusive dermatofibromas. Arch Dermatol. Apr 1990;126(4):522-3. [Medline].

  32. Shinojima Y, Hara H, Shimojima H, Terui T. Cutaneous chondroma with overlying pigmentation clinically mimicking dermatofibroma. Br J Dermatol. Jan 2006;154(1):178-81. [Medline].

  33. Sánchez Yus E, Soria L, de Eusebio E, Requena L. Lichenoid, erosive and ulcerated dermatofibromas. Three additional clinico-pathologic variants. J Cutan Pathol. Mar 2000;27(3):112-7. [Medline].

  34. Troxel DB. An insurer's perspective on error and loss in pathology. Arch Pathol Lab Med. Oct 2005;129(10):1234-6. [Medline].

  35. Wick MR, Ritter JH, Lind AC, Swanson PE. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans. Semin Cutan Med Surg. Mar 1999;18(1):91-8. [Medline].

  36. Zelger B, Zelger BG, Burgdorf WH. Dermatofibroma-a critical evaluation. Int J Surg Pathol. Oct 2004;12(4):333-44. [Medline].

  37. Zelger BG, Sidoroff A, Zelger B. Combined dermatofibroma: co-existence of two or more variant patterns in a single lesion. Histopathology. Jun 2000;36(6):529-39. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

DF, benign fibrous histiocytoma, dermal dendrocytoma, dermatofibroma lenticulare, fibroma durum, fibroma simplex, histiocytoma, histiocytoma cutis, nodular subepidermal fibrosis, sclerosing angioma, sclerosing hemangioma

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Joseph C Pierson, MD, Consulting Staff, Department of Dermatology, Keller Army Community Hospital
Joseph C Pierson, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Coauthor(s)

Diane M Pierson, DO, Fellow, Department of Hematopathology, MD Anderson Cancer Center, University of Texas at Houston
Diane M Pierson, DO is a member of the following medical societies: American Society of Hematology and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Medical Editor

Terry L Barrett, MD, Director, Associate Professor, Department of Dermatology, Division of Dermatopathology and Oral Pathology, Johns Hopkins University School of Medicine
Terry L Barrett, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society of Dermatopathology, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine
Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.